Wednesday, April 30, 2008

Parliamentary "Chemical Restraint" Report due later this month

Off-label use is the practice of prescribing drugs for a purpose outside the scope of the drug's approved label.  In the U.S. it is a criminal offense for a pharmaceutical company to promote off-label uses of drugs.  Atypical antipsychotics are not FDA approved for "Dementia".   Atypical antipsychotics have a black box warning "INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA" See FDA labels for Abilify, Geodon, Risperdal, Seroquel and Zyprexa here: http://tmap.wordpress.com/
 
WHEN David Ramsay, a former senior consultant at Guy’s hospital in London, was diagnosed with dementia in 1998, his wife fought for three years to have him taken into full-time care.

But just months after winning her battle, David’s neck twisted by 90 degrees, leaving his chin permanently fixed to his chest and forcing him to spend the rest of his life staring at the ground.

His condition, a rare neurological disorder, was a side-effect of a powerful antipsychotic drug prescribed to control the symptoms of Alzheimer’s. According to a parliamentary report, to be published later this month, his case is far from isolated.

No comments: